Core Viewpoint - Medtronic has announced a series of governance changes in collaboration with activist investor Elliott Investment Management, including the addition of two independent directors and the establishment of special committees focused on growth and operations [1][6][7]. Governance Changes - Two independent directors have been added to the board to enhance expertise in the medical device industry and financial governance [1][2]. - The CEO will chair one or two of the newly formed committees, emphasizing the importance of governance in driving company strategy [2]. Financial Performance - Medtronic reported its Q1 FY2026 earnings, raising its full-year EPS guidance to $5.60–$5.66, indicating confidence in operational improvements [3]. - The company achieved revenue of $8.58 billion, a year-on-year increase of 8.4%, with specific segments showing growth: $3.29 billion (9.3%) and $721 million (11.5%) [4]. Strategic Focus - Medtronic plans to spin off its diabetes business within the next 18 months, reflecting a shift in governance logic to enhance overall profitability and market valuation by divesting low-growth segments [7][9]. - The introduction of independent directors and special committees aligns with this strategic direction, signaling a move towards a more focused and streamlined business model [8][9]. Industry Implications - The governance reforms at Medtronic highlight a broader trend in the medical device industry, where companies are increasingly focusing on operational efficiency and asset concentration rather than maintaining a diverse portfolio [11][13]. - The involvement of capital forces is accelerating the strategic shifts among major medical device companies, leading to potential opportunities for smaller innovative firms within the industry ecosystem [11].

Group 1 - Medtronic's stock price has declined for two consecutive days, totaling a drop of 3.35%, reaching a new low since July 2025, which has attracted market attention [1] - Elliott Management has become a significant shareholder in Medtronic, advocating for changes in the company's governance structure, including the addition of two independent directors and the establishment of a special committee focused on growth and operations [1] - Despite Medtronic's Q1 FY2026 revenue of $8.6 billion, which exceeded market expectations of $8.4 billion, the stock price did not respond positively, indicating that the market may have already priced in the good news [1] Group 2 - Medtronic's recent actions reflect a proactive approach to seeking transformation through governance adjustments and sustained performance growth to enhance overall competitiveness [2] - Investors should monitor the subsequent impacts of these reforms and their support for the long-term development of the company's core business [2] - The stock price fluctuations of Medtronic illustrate the market's digestion process regarding the company's governance changes and performance [2]

Medtronic Today MDT Medtronic $96.25 Dividend Yield 3.19% P/E Ratio 24.56 Price Target $98.19 Add to Watchlist Medtronic's NYSE: MDT FQ1 results and guidance update did not spark a rally in the share price. Still, they did affirm a robust outlook that includes accelerating business growth, improving profitability, and reversing the stock price action. The critical takeaways are that growth was present, outperformed the consensus reported by MarketBeat, and guidance was improved. Get Medtronic alerts: Among ...

Guys, I wanted to uh diverge into activism for a Faber report uh this morning. Haven't gotten to it, but it's involving Metronic and of course the most active of activists, the most important activists that we have uh which is Elliot. Um and they were here uh they are there and there's already been change on the board.Two new independent directors have been appointed uh by Metronic, which by the way reported earnings as well this morning. Um uh they are both uh with significant uh experience are these gentl ...

Core Insights - Medtronic plc (MDT) reported first-quarter fiscal 2026 adjusted earnings per share (EPS) of $1.26, a 2.4% increase year-over-year, surpassing the Zacks Consensus Estimate by 2.4% [1][10] - The company's worldwide revenues for the quarter reached $8.58 billion, reflecting an 8.3% year-over-year increase and exceeding the Zacks Consensus Estimate by 2.5% [3][10] Revenue Breakdown - Cardiovascular segment revenues grew 7% organically to $3.23 billion, with Cardiac Rhythm & Heart Failure sales increasing 9.1% to $1.71 billion [5] - Medical Surgical revenues totaled $2.08 billion, up 2.4% year-over-year organically, with Surgical & Endoscopy revenues at $1.61 billion [6] - Neuroscience revenues reached $2.42 billion, a 3.1% organic increase, while Diabetes revenues rose 7.9% to $721 million [7] Margin Performance - Gross margin contracted by 10 basis points to 65% due to an 8.7% rise in the cost of revenues [8] - Adjusted operating margin expanded by 81 basis points year-over-year to 23.8% [8] Fiscal 2026 Outlook - Medtronic raised its full-year EPS outlook to $5.60-$5.66, with organic revenue growth projected at 5% [10][11] - The Zacks Consensus Estimate for fiscal 2026 worldwide revenues is $35.29 billion, indicating a 5.2% growth from the previous year [12] Strategic Developments - The company announced the addition of two independent directors and the formation of two special board committees focused on growth and operations, which may introduce short-term uncertainty [2]

Group 1 - The Zacks Style Scores provide a unique rating system for stocks based on value, growth, and momentum, helping investors identify securities with high potential to outperform the market in the short term [2][3][6] - Each stock is rated from A to F, with A indicating the highest potential for outperformance, and the Style Scores are categorized into Value Score, Growth Score, Momentum Score, and VGM Score [3][4][5] Group 2 - The Zacks Rank is a proprietary model that uses earnings estimate revisions to guide investors, with 1 (Strong Buy) stocks achieving an average annual return of +23.75% since 1988, significantly outperforming the S&P 500 [7][9] - Investors are encouraged to focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for the best chances of high returns [9][10] Group 3 - Medtronic, Inc. (MDT) is currently rated 3 (Hold) on the Zacks Rank, with a VGM Score of A, indicating it may be a suitable option for growth investors [11][12] - MDT is forecasted to have a year-over-year earnings growth of 1.1% for the current fiscal year, with a Zacks Consensus Estimate of $5.55 per share [12]

8月19日，美敦力(MDT)开盘下跌5.09%，截至21:30，报88.085美元/股，成交1.54亿美元，总市值 1128.60亿美元。 本文源自：金融界 作者：行情君 8月19日，美敦力2025年一季度累计回购金额1.23亿美元。 资料显示，美国美敦力有限公司 ("美敦力") 总部位于爱尔兰都柏林,是世界上最大的医疗技术、服务和 解决方案公司之一。美敦力成立于1949年,该公司向150多个国家的医院、医生、临床医生和患者提供产 品。该公司仍然致力于创始人在1960年确立的使命:"通过应用生物医学工程来研究、设计、制造和销售 减轻疼痛、恢复健康和延长寿命的产品,以造福人类。" 财务数据显示，截至2025年07月25日，美敦力收入总额85.78亿美元，同比增长8.38%；归母净利润10.4 亿美元，同比减少0.19%。 大事提醒： ...

Financial Data and Key Metrics Changes - The company reported Q1 revenue of €8.6 billion, growing 8.4% reported and 4.8% organic, in line with guidance [38] - Adjusted EPS was €1.26, exceeding the midpoint of guidance by €0.03 [42] - Adjusted gross margin was 65.1%, down 80 basis points year over year, but stable compared to Q4 [38] Business Line Data and Key Metrics Changes - Cardiovascular grew 7% this quarter, driven by nearly 50% growth in Cardiac Ablation Solutions [21][22] - Neuroscience grew 3%, with high single-digit growth in neurosurgery and neuromodulation [11][28] - MedSurg grew 2%, with high single-digit growth in Advanced Energy [31] - Diabetes grew 8%, with 11% growth in international markets [34] Market Data and Key Metrics Changes - The U.S. market showed slower growth in certain segments, particularly in diabetes and pelvic health, while international markets performed better [60] - The company expects to ramp up procedures for the SIMPLICITY system following CMS's proposed national coverage decision [25][27] Company Strategy and Development Direction - The company is focused on accelerating growth through innovation and strategic investments in high-growth areas like CAS and Ardian [19][20] - A planned separation of the diabetes business is expected to enhance focus on core businesses and improve revenue and earnings growth [19][37] - New board committees have been established to enhance focus on growth and operational efficiency [48][49] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in accelerating growth in the second half of fiscal 2026, driven by strong demand and new product launches [7][19] - The company anticipates significant revenue growth from its PFA portfolio and other upcoming product launches [13][14] - Management highlighted the importance of maintaining pricing discipline and improving operational efficiencies to support growth [38][45] Other Important Information - The company is increasing investments in R&D, with a 7.7% increase in adjusted R&D spending [40] - The anticipated impact of tariffs has been adjusted, with expectations now at approximately €185 million for fiscal 2026 [44] Q&A Session All Questions and Answers Question: Update on CAS growth and its impact on U.S. growth - Management confirmed that CAS growth is accelerating and will positively impact U.S. growth, despite some segments showing slower growth [56][58] Question: Impact of new board committees on governance and operations - The new committees will provide focused oversight on growth and operational performance, with increased interaction with management expected to drive improvements [68][70] Question: Commitment to CAS annual sales target - Management reaffirmed the commitment to achieving $2 billion in annual CAS sales, indicating strong confidence in the growth trajectory [76][78] Question: Discussion on capital allocation and potential changes - Management indicated that the new board members and committees will facilitate discussions on capital allocation and value creation strategies [81][89] Question: Overall portfolio growth expectations - Management stated that while significant growth opportunities exist, they will not neglect the rest of the business and expect to see incremental growth from various segments [99][100]

Financial Data and Key Metrics Changes - The company reported Q1 revenue of €8.6 billion, growing 8.4% reported and 4.8% organic, in line with guidance [38] - Adjusted EPS was €1.26, exceeding the midpoint of guidance by €0.03 [42] - Adjusted gross margin was 65.1%, down 80 basis points year over year, but stable compared to Q4 [38][39] Business Line Data and Key Metrics Changes - Cardiovascular grew 7% this quarter, with cardiac ablation solutions achieving nearly 50% growth [20][21] - Neuroscience grew 3%, with high single-digit growth in neurosurgery and neuromodulation [10][27] - MedSurg grew 2%, with advanced energy showing high single-digit growth [31] - Diabetes grew 8%, driven by the strength of the 780G system and Simplera Sync Sensor in international markets [34] Market Data and Key Metrics Changes - The U.S. market showed slower growth in certain segments, particularly in diabetes and pelvic health, while international markets performed better [61] - CAS growth was particularly strong in the U.S. and Japan, with low 70s growth in the U.S. and low 30s growth internationally [20][21] Company Strategy and Development Direction - The company is focused on accelerating growth through innovation in med tech and has raised its EPS guidance for the full year [6][7] - A planned separation of the diabetes business is expected to sharpen focus on core high-growth opportunities [17][37] - New board committees have been established to enhance focus on growth and operational efficiency [49][50] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to accelerate growth throughout fiscal 2026, citing strong demand and a robust product pipeline [6][17] - The company anticipates significant growth from the cardiac ablation solutions and renal denervation segments [12][13] - Management highlighted the importance of operational efficiency and innovation to drive long-term shareholder value [18][46] Other Important Information - The company expects to finalize the national coverage determination for the simplicity procedure for hypertension by October 8 [25] - The company is investing significantly in R&D, with a 7.7% increase in adjusted R&D spending [40] Q&A Session Summary Question: Update on CAS growth and its impact on U.S. growth - Management confirmed confidence in CAS growth, noting strong demand and utilization, and expects it to positively impact U.S. growth in the future [56][60] Question: Impact of new board committees on governance and capital allocation - Management explained that the new committees will provide focused oversight on growth and operational performance, enhancing communication with management [70][72] Question: Commitment to CAS annual sales target - Management reiterated commitment to the $2 billion annual sales target for CAS, indicating strong momentum and confidence in achieving this goal [76][78] Question: Discussion on capital allocation and EPS growth - Management emphasized a renewed focus on value creation, including potential M&A opportunities and increased investment in growth drivers [81][86] Question: Overall portfolio growth expectations - Management indicated that while significant growth drivers are emerging, the overall business will continue to improve, with a focus on maintaining operational efficiency and EPS growth [95][100]

Group 1 - Medtronic reported quarterly earnings of $1.26 per share, exceeding the Zacks Consensus Estimate of $1.23 per share, and showing an increase from $1.23 per share a year ago, resulting in an earnings surprise of +2.44% [1] - The company achieved revenues of $8.58 billion for the quarter ended July 2025, surpassing the Zacks Consensus Estimate by 2.50%, and up from $7.92 billion year-over-year [2] - Medtronic has outperformed the S&P 500 with a share price increase of about 16.2% since the beginning of the year, compared to the S&P 500's gain of 9.7% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is $1.33 on revenues of $8.73 billion, and for the current fiscal year, it is $5.55 on revenues of $35.29 billion [7] - The Zacks Industry Rank indicates that the Medical - Products industry is in the top 39% of over 250 Zacks industries, suggesting that stocks in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8]